Wearables in Pharma & Biotech Market by Product (Smartwatches, CGMs, Bands, Rings, Patches, Injectors), Therapy (Diabetes, Cardio, Onco, Mental Health), Application (Drug Discovery, Clinical Trials, Medication Adherence), End User - Global Forecasts to 2031
The wearables in pharma & biotech market is projected to reach USD 9.97 billion by 2031 from USD 3.98 billion in 2026, at a CAGR of 20.2%. The market is driven by rapid technological developments in biosensors, miniaturization, and digitization. Increasing global digital connectivity is another significant facilitator of the expanding wearable market. The International Telecommunication Union reported that over 5.4 billion people worldwide were using the internet in 2023. This widespread connectivity is enabling the seamless integration of data from wearable devices into cloud environments. Additionally, the All of Us Research Program has recruited more than 500,000 participants, some of whom are contributing data from wearables, including activity levels, heart rate, and sleep patterns. This reflects the growing role of wearable technology in large-scale biomedical research and precision medicine. This growth is further supported by the increasing adoption of remote patient monitoring (RPM) and digital care solutions. In the US, the Centers for Medicare & Medicaid Services reported a substantial increase in reimbursement claims for remote physiological monitoring services following the expansion of the policy in 2022. This indicates widespread adoption of wearable-derived care among healthcare providers. In addition, developments in the accuracy of sensors and multi-parameter monitoring are allowing wearables to measure clinically significant endpoints beyond basic vital signs. This is expanding the scope of wearables in drug safety and therapeutic studies.
“By product, continuous glucose monitors (CGMs) segment to account for largest market share”
The product segment is divided into smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), patches, wearable injectors, and others. The CGMs segment has a large market share due to the high level of support from clinical guidelines, increasing scope of eligible patients, and the ability of the devices to be used with the most advanced diabetic management systems. The American Diabetes Association recommends the use of CGMs for a broad population of diabetic patients, as per the 2024 Standards of Care, thereby increasing the scope of the market. Furthermore, the availability of reimbursement schemes for hundreds of thousands of patients through the National Health Service has also helped the market expand in the region. In addition, approvals by the Food and Drug Administration for interoperable CGMs used in conjunction with insulin delivery systems have also helped the market expand in the region. The devices also provide up to 288 glucose readings in a day, making them highly valuable in the market .
“By end user, pharmaceutical and biotech companies accounted for largest market share in 2025”
Pharmaceutical and biotech companies dominated the market for wearables in the pharma & biotech market in terms of market share in 2025. This is mainly attributed to the complexity of clinical trials, where pharmaceutical and biotech companies require wearable technologies for data collection. According to a study by the Tufts Center for the Study of Drug Development, clinical trial protocols currently involve more than 20 endpoints on average, thus increasing the requirement for data collection. Wearable technologies are increasingly being used in this context. Furthermore, large-scale research initiatives, such as the UK Biobank, have successfully used wearable technologies for data collection from over 100,000 individuals, thus highlighting the potential of wearable technologies in pharmaceutical research. Considering this, pharmaceutical and biotech companies are likely to remain a dominant end user in this market .
“Asia Pacific to witness highest growth rate during forecast period”
The Asia Pacific (APAC) region is experiencing the highest growth rate in the wearables in pharma & biotech market. This growth can be attributed to several factors, including improvements in digital health infrastructure, a rise in clinical research activities, and a significant number of underserved patients. According to the WHO, the combined Western Pacific and Southeast Asia regions contribute a large share to the world's disease burden. It has been mentioned by the International Telecommunication Union that the penetration of the Internet in the APAC region has surpassed 66% to 70% in recent years. Additionally, it has been observed that countries like China and India are emerging as hubs for clinical trials, with thousands of trials already conducted in these regions. Technology is being adopted to enhance the efficiency of these trials. In September 2024, Biobeat announced its expansion into Argentina and Chile through a partnership with Infinity Pharma.
The breakdown of primary participants is as given below:
This research report categorizes the wearables in pharma & biotech market by Product (Smartwatches, Fitness Bands, Smart Rings, Continuous Glucose Monitors (CGM), Patches, Wearable Injectors, Others), Therapeutic Area (cardiovascular (atherosclerotic cardiovascular disease (ASCVD) / secondary prevention, heart failure (HFREF and HFPEF), hypertension, atrial fibrillation (AF) / stroke prevention, pulmonary hypertension, structural heart disease / interventional cardiology), oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders / pain management, women’s health & reproductive health, other diseases), Application (drug discovery, clinical trials (phase ii, phase iii, phase iv), medication adherence & behavioral support, chronic disease monitoring, personalized & preventive digital therapeutics), end user (pharmaceutical & biotech companies, healthcare providers & clinicians, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the wearables in pharma & biotech market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the wearables in pharma & biotech market. Competitive analysis of upcoming startups in the market ecosystem is covered in this report.
Reasons to Buy this Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the wearables in pharma & biotech market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“By product, continuous glucose monitors (CGMs) segment to account for largest market share”
The product segment is divided into smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), patches, wearable injectors, and others. The CGMs segment has a large market share due to the high level of support from clinical guidelines, increasing scope of eligible patients, and the ability of the devices to be used with the most advanced diabetic management systems. The American Diabetes Association recommends the use of CGMs for a broad population of diabetic patients, as per the 2024 Standards of Care, thereby increasing the scope of the market. Furthermore, the availability of reimbursement schemes for hundreds of thousands of patients through the National Health Service has also helped the market expand in the region. In addition, approvals by the Food and Drug Administration for interoperable CGMs used in conjunction with insulin delivery systems have also helped the market expand in the region. The devices also provide up to 288 glucose readings in a day, making them highly valuable in the market .
“By end user, pharmaceutical and biotech companies accounted for largest market share in 2025”
Pharmaceutical and biotech companies dominated the market for wearables in the pharma & biotech market in terms of market share in 2025. This is mainly attributed to the complexity of clinical trials, where pharmaceutical and biotech companies require wearable technologies for data collection. According to a study by the Tufts Center for the Study of Drug Development, clinical trial protocols currently involve more than 20 endpoints on average, thus increasing the requirement for data collection. Wearable technologies are increasingly being used in this context. Furthermore, large-scale research initiatives, such as the UK Biobank, have successfully used wearable technologies for data collection from over 100,000 individuals, thus highlighting the potential of wearable technologies in pharmaceutical research. Considering this, pharmaceutical and biotech companies are likely to remain a dominant end user in this market .
“Asia Pacific to witness highest growth rate during forecast period”
The Asia Pacific (APAC) region is experiencing the highest growth rate in the wearables in pharma & biotech market. This growth can be attributed to several factors, including improvements in digital health infrastructure, a rise in clinical research activities, and a significant number of underserved patients. According to the WHO, the combined Western Pacific and Southeast Asia regions contribute a large share to the world's disease burden. It has been mentioned by the International Telecommunication Union that the penetration of the Internet in the APAC region has surpassed 66% to 70% in recent years. Additionally, it has been observed that countries like China and India are emerging as hubs for clinical trials, with thousands of trials already conducted in these regions. Technology is being adopted to enhance the efficiency of these trials. In September 2024, Biobeat announced its expansion into Argentina and Chile through a partnership with Infinity Pharma.
The breakdown of primary participants is as given below:
- By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
- By Designation - C-level: 30%, Director-level: 50%, and Others: 20%
- By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the World: 10%.
- The study includes an in-depth competitive analysis of these key players in the wearables in pharma & biotech market, with their company profiles, recent developments, and key market strategies.
This research report categorizes the wearables in pharma & biotech market by Product (Smartwatches, Fitness Bands, Smart Rings, Continuous Glucose Monitors (CGM), Patches, Wearable Injectors, Others), Therapeutic Area (cardiovascular (atherosclerotic cardiovascular disease (ASCVD) / secondary prevention, heart failure (HFREF and HFPEF), hypertension, atrial fibrillation (AF) / stroke prevention, pulmonary hypertension, structural heart disease / interventional cardiology), oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders / pain management, women’s health & reproductive health, other diseases), Application (drug discovery, clinical trials (phase ii, phase iii, phase iv), medication adherence & behavioral support, chronic disease monitoring, personalized & preventive digital therapeutics), end user (pharmaceutical & biotech companies, healthcare providers & clinicians, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the wearables in pharma & biotech market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the wearables in pharma & biotech market. Competitive analysis of upcoming startups in the market ecosystem is covered in this report.
Reasons to Buy this Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the wearables in pharma & biotech market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Shift toward value-based and patient-centric healthcare models, Rising prevalence of chronic diseases requiring continuous patient monitoring, Rapid digitalization of healthcare and expansion of telehealth services) restraints (High implementation and integration costs for healthcare providers, Data privacy and cybersecurity concerns) opportunities (Expansion of remote patient monitoring and home-based care models, Integration of advanced analytics and personalized healthcare) and challenges (Interoperability limitations with existing healthcare IT systems, Low patient adoption and digital literacy barriers) influencing the growth of the wearables in pharma & biotech market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the wearables in pharma & biotech market
- Market Development: Comprehensive information about lucrative markets; the report analyses the wearables in pharma & biotech market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the wearables in pharma & biotech market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like BD (US), Abbott (US), Masimo (US), DexCom, Inc. (US), Medtronic (Ireland), among others, in the wearables in pharma & biotech market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 UNIT CONSIDERED
1.6 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING WEARABLES IN PHARMA & BIOTECH MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR WEARABLES IN PHARMA & BIOTECH MARKET
3.2 NORTH AMERICA WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER AND COUNTRY
3.3 WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Shift toward value-based and patient-centric healthcare models
4.2.1.2 Prevalence of chronic diseases requiring continuous patient monitoring
4.2.1.3 Rapid digitalization of healthcare and expansion of telehealth services
4.2.2 RESTRAINTS
4.2.2.1 High implementation and integration costs
4.2.2.2 Data privacy and cybersecurity concerns
4.2.3 OPPORTUNITIES
4.2.3.1 Expansion of remote patient monitoring and home-based care models
4.2.3.2 Integration of advanced analytics and personalized healthcare
4.2.4 CHALLENGES
4.2.4.1 Limited interoperability with existing healthcare IT systems
4.2.4.2 Low patient adoption and digital literacy barriers
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE)
5.1.2 BARGAINING POWER OF BUYERS (MODERATE TO HIGH)
5.1.3 THREAT OF SUBSTITUTES (LOW TO MODERATE)
5.1.4 THREAT OF NEW ENTRANTS (MODERATE)
5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH)
5.2 MACROECONOMIC INDICATORS
5.2.1 GDP TRENDS AND FORECAST
5.2.2 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY PRODUCT, 2025
5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT DATA (HS CODE 9018)
5.6.2 EXPORT DATA (HS CODE 9018)
5.7 KEY CONFERENCES AND EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 INVESTMENT AND FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
5.11 IMPACT OF 2025 US TARIFF
5.11.1 KEY TARIFF RATES
5.11.2 PRICE IMPACT ANALYSIS
5.11.3 IMPACT ON COUNTRIES/REGIONS
5.11.3.1 US
5.11.3.2 Europe
5.11.3.3 Asia Pacific
5.11.4 IMPACT ON END-USE INDUSTRIES
5.11.4.1 Pharmaceutical & biotech companies
5.11.4.2 Healthcare providers & clinicians
5.11.4.3 Other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY TECHNOLOGIES
6.1.1 ADVANCED BIOSENSING AND MULTI-PARAMETER WEARABLES
6.1.2 AI-DRIVEN ANALYTICS AND CLINICAL INTELLIGENCE
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MOBILE HEALTH AND REMOTE PATIENT MONITORING
6.2.2 ANALYTICS AND POPULATION-LEVEL HEALTH DATA INTEGRATION
6.3 ADJACENT TECHNOLOGIES
6.3.1 INTERNET OF MEDICAL THINGS AND CONNECTED DEVICES
6.3.2 CLOUD AND EDGE COMPUTING
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 PATENT PUBLICATION TRENDS
6.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS
6.6 FUTURE APPLICATIONS
6.6.1 AI-DRIVEN PREDICTIVE MONITORING AND CLINICAL DECISION SUPPORT
6.6.2 CLOSED-LOOP THERAPEUTIC AND DRUG DELIVERY SYSTEMS
6.6.3 DECENTRALIZED AND HYBRID CLINICAL TRIAL ENABLEMENT
6.6.4 CONTINUOUS DISEASE MANAGEMENT AND PREVENTIVE HEALTHCARE
6.6.5 ADVANCED BIOSENSING AND NON-INVASIVE DIAGNOSTICS
6.6.6 INTEGRATION WITH DIGITAL THERAPEUTICS AND PERSONALIZED MEDICINE
6.7 IMPACT OF AI/GEN AI
6.7.1 MARKET POTENTIAL OF AI/GEN AI
6.7.2 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
6.7.2.1 AI-driven continuous glucose monitoring and diabetes management at Dexcom
6.7.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
6.7.3.1 Wearable data analytics and AI-driven monitoring platforms
6.7.3.2 Digital health platforms, integration, and regulatory infrastructure
6.7.3.3 Clinical care, remote monitoring, and personalized therapeutics
6.7.4 USER READINESS AND IMPACT ASSESSMENT
6.7.4.1 User readiness
6.7.4.1.1 User A: Hospitals, clinics, and long-term care providers
6.7.4.1.2 User B: Pharma and biotech companies
6.7.4.2 Impact assessment
6.7.4.2.1 User A: Hospitals, clinics, and long-term care providers
6.7.4.2.1.1 Implementation
6.7.4.2.1.2 Impact
6.7.4.2.2 User B: Pharma and biotech companies
6.7.4.2.2.1 Implementation
6.7.4.2.2.2 Impact
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END-USE INDUSTRIES
8.4.1 UNMET NEEDS
8.4.2 END-USER EXPECTATIONS
8.5 MARKET PROFITABILITY
9 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 SMARTWATCHES
9.2.1 EXPANDING ROLE IN DIGITAL CLINICAL TRIALS AND REMOTE MONITORING
9.3 FITNESS BANDS
9.3.1 EMPHASIS ON REAL-WORLD EVIDENCE AND PATIENT-CENTRIC TRIAL DESIGNS
9.4 SMART RINGS
9.4.1 EMERGING CLINICAL-GRADE WEARABLES ENABLING EARLY DISEASE DETECTION AND CONTINUOUS MONITORING
9.5 CONTINUOUS GLUCOSE MONITORS
9.5.1 TRANSFORMING METABOLIC RESEARCH THROUGH REAL-TIME, HIGH-FREQUENCY DATA
9.6 PATCHES
9.6.1 CONTINUOUS, CLINICAL-GRADE MONITORING DRIVING ADOPTION IN DECENTRALIZED TRIALS
9.7 WEARABLE INJECTORS
9.7.1 GROWING DEMAND FOR SELF-ADMINISTRATION OF BIOLOGICS IN CHRONIC DISEASE MANAGEMENT
9.8 OTHER PRODUCTS
10 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA
10.1 INTRODUCTION
10.2 CARDIOVASCULAR
10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION
10.2.1.1 Focus on improving endpoint capture and long-term outcomes monitoring
10.2.2 HEART FAILURE
10.2.2.1 Continuous physiologic monitoring and AI-enabled decompensation prediction
10.2.3 HYPERTENSION
10.2.3.1 Cuffless monitoring and AI-driven adherence management enabling precision blood pressure control
10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION
10.2.4.1 Rapid expansion of AI-powered arrhythmia detection algorithms and regulatory-cleared wearable ECG technologies
10.2.5 PULMONARY HYPERTENSION
10.2.5.1 Growing use of wearable-enabled remote monitoring and AI analytics to generate objective, real-world functional endpoints
10.2.6 STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY
10.2.6.1 Wearable-enabled remote recovery monitoring and procedural optimization supporting precision structural heart care
10.3 ONCOLOGY
10.3.1 SOLID TUMORS
10.3.1.1 BREAST CANCER
10.3.1.1.1 Continuous wearable-based survivorship monitoring and decentralized oncology trials driving personalized long-term care models
10.3.1.2 LUNG CANCER
10.3.1.2.1 Constant respiratory monitoring and decentralized trial adoption
10.3.1.3 PROSTATE CANCER
10.3.1.3.1 Expansion of decentralized oncology trials and long-term survivorship management
10.3.1.4 COLORECTAL CANCER
10.3.1.4.1 Increasing adoption of decentralized oncology trials and remote post-surgical monitoring
10.3.1.5 BRAIN TUMOR
10.3.1.5.1 Remote neurologic surveillance and functional recovery tracking accelerating personalized care
10.3.1.6 OTHER SOLID TUMORS
10.3.2 HEMATOLOGIC MALIGNANCIES
10.3.2.1 LEUKEMIA
10.3.2.1.1 Wearable-enabled infection surveillance and treatment resilience monitoring transforming outpatient care
10.3.2.2 LYMPHOMA
10.3.2.2.1 Shift toward outpatient infusion centers, home-based recovery, and decentralized clinical trials
10.3.2.3 MULTIPLE MYELOMA
10.3.2.3.1 Real-time toxicity and mobility tracking using wearables in long-term management
10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES
10.3.3 DIABETES
10.3.3.1 Critical need for long-term, real-world metabolic monitoring
10.3.4 MENTAL HEALTH & BEHAVIORAL HEALTH
10.3.4.1 Rising global burden of psychiatric disorders
10.3.5 RESPIRATORY DISORDERS
10.3.5.1 Early exacerbation detection through continuous monitoring reduces hospitalization
10.3.6 LIFESTYLE & WELLNESS IMPROVEMENT
10.3.6.1 Continuous tracking for lifestyle optimization and preventive health risk management
10.3.7 NEUROLOGY
10.3.7.1 Wearable-based monitoring of neurological function and digital clinical endpoints in CNS disorders
10.3.8 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
10.3.8.1 Wearable-guided functional movement and chronic pain monitoring in musculoskeletal disorders
10.3.9 WOMEN'S HEALTH & REPRODUCTIVE HEALTH
10.3.9.1 Continuous physiological and reproductive cycle using wearables
10.3.10 OTHER DISEASES
11 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DRUG DISCOVERY
11.2.1 RECENT ADVANCES PROMOTE DISCOVERY OF DRUGS THROUGH WEARABLES IN PHARMA & BIOTECH
11.3 CLINICAL TRIALS
11.3.1 PHASE II
11.3.1.1 AI-enabled remote monitoring and adaptive trial designs accelerate adoption
11.3.2 PHASE III
11.3.2.1 Rapid expansion of decentralized and hybrid global trial models propels growth
11.3.3 PHASE IV
11.3.3.1 Ability to improve patient engagement and retention in long-duration studies drives market
11.4 MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
11.4.1 CONNECTED REMINDERS, PASSIVE MONITORING, AND PERSONALIZED NUDGES BOOST ADOPTION
11.5 CHRONIC DISEASE MONITORING
11.5.1 CONTINUOUS PHYSIOLOGICAL TRACKING AND PROACTIVE INTERVENTION CAPABILITIES INCREASE ADOPTION
11.6 PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
11.6.1 BIOMETRIC SENSING AND AI-DRIVEN COACHING RAISE DEMAND FOR WEARABLES
12 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOTECH COMPANIES
12.2.1 CLINICAL DIGITIZATION, REAL-WORLD EVIDENCE GENERATION, AND CONNECTED THERAPY MODELS DRIVE MARKET
12.3 HEALTHCARE PROVIDERS & CLINICIANS
12.3.1 REMOTE PATIENT MONITORING, PREVENTIVE CARE, AND DATA-DRIVEN CLINICAL DECISION SUPPORT BOOST GROWTH
12.4 CONTRACT RESEARCH ORGANIZATIONS
12.4.1 DECENTRALIZED TRIALS, WEARABLE DATA INTEGRATION, AND FASTER CLINICAL EXECUTION RAISE DEMAND
12.5 OTHER END USERS
13 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 High concentration of clinical research activity, clinical trial inefficiencies, and cost pressures to drive market
13.2.2 CANADA
13.2.2.1 Clinical research participation, public health burden, and digital health adoption to drive market
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Expanding clinical trial activity and regulatory leadership to drive market
13.3.2 FRANCE
13.3.2.1 Regulatory-first approach to healthcare and clinical innovation to drive market
13.3.3 UK
13.3.3.1 Real-world data integration and decentralized trial innovation to drive market
13.3.4 ITALY
13.3.4.1 Evolving clinical trial landscape and regulatory decentralization to drive market
13.3.5 SPAIN
13.3.5.1 Increasing investment in digital health infrastructure to drive market
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Clinical trial expansion and real-world data integration to drive market
13.4.2 JAPAN
13.4.2.1 Late-stage trial leadership and regulatory precision to drive market
13.4.3 INDIA
13.4.3.1 High-volume Phase III trial ecosystem and ABDM-driven digital health integration to drive market
13.4.4 AUSTRALIA
13.4.4.1 Early-phase trial leadership and remote care needs to drive market
13.4.5 SOUTH KOREA
13.4.5.1 Integrated clinical trial ecosystem and national health data infrastructure to drive market
13.4.6 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Clinical trial leadership and high diabetes burden to drive market
13.5.2 MEXICO
13.5.2.1 Regulatory reforms and Phase III trial expansion to drive market
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST & AFRICA
13.6.1 GCC
13.6.2 SAUDI ARABIA
13.6.2.1 Vision 2030–led digital health transformation to drive market
13.6.3 UAE
13.6.3.1 Digital health strategy, clinical trial expansion, and high healthcare investment to drive market
13.6.4 REST OF GCC
13.6.5 SOUTH AFRICA
13.6.5.1 Clinical trial leadership and decentralized care models to drive market
13.6.6 REST OF MIDDLE EAST & AFRICA
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026
14.3 REVENUE ANALYSIS, 2021–2025
14.4 MARKET SHARE ANALYSIS, 2025
14.5 BRAND/PRODUCT COMPARISON
14.6 COMPANY VALUATION AND FINANCIAL METRICS
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.7.1 STARS
14.7.2 EMERGING LEADERS
14.7.3 PERVASIVE PLAYERS
14.7.4 PARTICIPANTS
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
14.7.5.1 Company footprint
14.7.5.2 Region footprint
14.7.5.3 Product footprint
14.7.5.4 Therapeutic area footprint
14.7.5.5 Application footprint
14.7.5.6 End user footprint
14.8 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025
14.8.1 PROGRESSIVE COMPANIES
14.8.2 RESPONSIVE COMPANIES
14.8.3 DYNAMIC COMPANIES
14.8.4 STARTING BLOCKS
14.8.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025
14.8.5.1 List of start-ups/SMEs
14.8.5.2 Competitive benchmarking of start-ups/SMEs
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES AND APPROVALS
14.9.2 DEALS
14.9.3 OTHER DEVELOPMENTS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 DEXCOM, INC.
15.1.1.1 Business overview
15.1.1.2 Products offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches and approvals
15.1.1.3.2 Deals
15.1.1.4 MnM view
15.1.1.4.1 Right to win
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 ABBOTT
15.1.2.1 Business overview
15.1.2.2 Products offered
15.1.2.3 Recent developments
15.1.2.3.1 Product launches and approvals
15.1.2.3.2 Deals
15.1.2.3.3 Other developments
15.1.2.4 MnM view
15.1.2.4.1 Right to win
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses and competitive threats
15.1.3 MASIMO
15.1.3.1 Business overview
15.1.3.2 Products offered
15.1.3.3 Recent developments
15.1.3.3.1 Product launches and approvals
15.1.3.3.2 Deals
15.1.3.4 MnM view
15.1.3.4.1 Right to win
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses and competitive threats
15.1.4 BD
15.1.4.1 Business overview
15.1.4.2 Products offered
15.1.4.3 Recent developments
15.1.4.3.1 Product launches and approvals
15.1.4.3.2 Deals
15.1.4.4 MnM view
15.1.4.4.1 Right to win
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 APPLE INC.
15.1.5.1 Business overview
15.1.5.2 Products offered
15.1.5.3 Recent developments
15.1.5.3.1 Product launches and approvals
15.1.5.3.2 Deals
15.1.5.4 MnM view
15.1.5.4.1 Right to win
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses and competitive threats
15.1.6 BOSTON SCIENTIFIC CORPORATION
15.1.6.1 Business overview
15.1.6.2 Products offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.7 IRHYTHM TECHNOLOGIES, INC.
15.1.7.1 Business overview
15.1.7.2 Products offered
15.1.7.3 Recent developments
15.1.7.3.1 Product launches and approvals
15.1.7.3.2 Deals
15.1.8 KONINKLIJKE PHILIPS N.V.
15.1.8.1 Business overview
15.1.8.2 Products offered
15.1.8.3 Recent developments
15.1.8.3.1 Product launches and approvals
15.1.8.3.2 Deals
15.1.8.3.3 Other developments
15.1.9 MEDTRONIC
15.1.9.1 Business overview
15.1.9.2 Products offered
15.1.9.3 Recent developments
15.1.9.3.1 Deals
15.1.10 BIOINTELLISENSE, INC.
15.1.10.1 Business overview
15.1.10.2 Products offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches and approvals
15.1.10.3.2 Deals
15.1.11 F. HOFFMANN-LA ROCHE LTD
15.1.11.1 Business overview
15.1.11.2 Products offered
15.1.11.3 Recent developments
15.1.11.3.1 Product launches and approvals
15.1.12 GE HEALTHCARE
15.1.12.1 Business overview
15.1.12.2 Products offered
15.1.12.3 Recent developments
15.1.12.3.1 Product launches and approvals
15.1.12.3.2 Deals
15.1.13 BIOBEAT
15.1.13.1 Business overview
15.1.13.2 Products offered
15.1.13.3 Recent developments
15.1.13.3.1 Product launches and approvals
15.1.13.3.2 Deals
15.1.13.3.3 Other developments
15.1.14 EMPATICA INC.
15.1.14.1 Business overview
15.1.14.2 Products offered
15.1.14.3 Recent developments
15.1.14.3.1 Product launches and approvals
15.1.14.3.2 Deals
15.1.15 VITALCONNECT
15.1.15.1 Business overview
15.1.15.2 Products offered
15.1.15.3 Recent developments
15.1.15.3.1 Deals
15.1.15.3.2 Other developments
15.1.16 AMETRIS, LLC
15.1.16.1 Business overview
15.1.16.2 Products offered
15.1.16.3 Recent developments
15.1.16.3.1 Deals
15.1.17 ALIVECOR, INC.
15.1.17.1 Business overview
15.1.17.2 Products offered
15.1.17.3 Recent developments
15.1.17.3.1 Product launches and approvals
15.1.17.3.2 Deals
15.1.18 WITHINGS
15.1.18.1 Business overview
15.1.18.2 Products offered
15.1.18.3 Recent developments
15.1.18.3.1 Product launches and approvals
15.1.18.3.2 Deals
15.1.19 VIVALNK, INC.
15.1.19.1 Business overview
15.1.19.2 Products offered
15.1.19.3 Recent developments
15.1.19.3.1 Product launches and approvals
15.1.20 MEDIBIOSENSE
15.1.20.1 Business overview
15.1.20.2 Products offered
15.1.20.3 Recent developments
15.1.20.3.1 Product launches and approvals
15.2 OTHER PLAYERS
15.2.1 SIBEL HEALTH, INC.
15.2.2 BYTEFLIES
15.2.3 STRADOS LABS
15.2.4 ONERA TECHNOLOGIES B.V.
15.2.5 EPICORE BIOSYSTEMS, INC.
16 RESEARCH METHODOLOGY
16.1 RESEARCH APPROACH
16.1.1 SECONDARY RESEARCH
16.1.1.1 Key data from secondary sources
16.1.2 PRIMARY RESEARCH
16.1.2.1 Primary sources
16.1.2.2 Key data from primary sources
16.1.2.3 Breakdown of primary interviews
16.1.2.4 Insights from primary experts
16.2 RESEARCH METHODOLOGY DESIGN
16.3 MARKET SIZE ESTIMATION
16.4 DATA TRIANGULATION
16.5 RESEARCH ASSUMPTIONS
16.6 RESEARCH LIMITATIONS
16.6.1 METHODOLOGY-RELATED
16.6.2 SCOPE-RELATED
16.7 RISK ASSESSMENT
17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 UNIT CONSIDERED
1.6 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING WEARABLES IN PHARMA & BIOTECH MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR WEARABLES IN PHARMA & BIOTECH MARKET
3.2 NORTH AMERICA WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER AND COUNTRY
3.3 WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Shift toward value-based and patient-centric healthcare models
4.2.1.2 Prevalence of chronic diseases requiring continuous patient monitoring
4.2.1.3 Rapid digitalization of healthcare and expansion of telehealth services
4.2.2 RESTRAINTS
4.2.2.1 High implementation and integration costs
4.2.2.2 Data privacy and cybersecurity concerns
4.2.3 OPPORTUNITIES
4.2.3.1 Expansion of remote patient monitoring and home-based care models
4.2.3.2 Integration of advanced analytics and personalized healthcare
4.2.4 CHALLENGES
4.2.4.1 Limited interoperability with existing healthcare IT systems
4.2.4.2 Low patient adoption and digital literacy barriers
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE)
5.1.2 BARGAINING POWER OF BUYERS (MODERATE TO HIGH)
5.1.3 THREAT OF SUBSTITUTES (LOW TO MODERATE)
5.1.4 THREAT OF NEW ENTRANTS (MODERATE)
5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH)
5.2 MACROECONOMIC INDICATORS
5.2.1 GDP TRENDS AND FORECAST
5.2.2 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY PRODUCT, 2025
5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT DATA (HS CODE 9018)
5.6.2 EXPORT DATA (HS CODE 9018)
5.7 KEY CONFERENCES AND EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 INVESTMENT AND FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
5.11 IMPACT OF 2025 US TARIFF
5.11.1 KEY TARIFF RATES
5.11.2 PRICE IMPACT ANALYSIS
5.11.3 IMPACT ON COUNTRIES/REGIONS
5.11.3.1 US
5.11.3.2 Europe
5.11.3.3 Asia Pacific
5.11.4 IMPACT ON END-USE INDUSTRIES
5.11.4.1 Pharmaceutical & biotech companies
5.11.4.2 Healthcare providers & clinicians
5.11.4.3 Other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY TECHNOLOGIES
6.1.1 ADVANCED BIOSENSING AND MULTI-PARAMETER WEARABLES
6.1.2 AI-DRIVEN ANALYTICS AND CLINICAL INTELLIGENCE
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MOBILE HEALTH AND REMOTE PATIENT MONITORING
6.2.2 ANALYTICS AND POPULATION-LEVEL HEALTH DATA INTEGRATION
6.3 ADJACENT TECHNOLOGIES
6.3.1 INTERNET OF MEDICAL THINGS AND CONNECTED DEVICES
6.3.2 CLOUD AND EDGE COMPUTING
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 PATENT PUBLICATION TRENDS
6.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS
6.6 FUTURE APPLICATIONS
6.6.1 AI-DRIVEN PREDICTIVE MONITORING AND CLINICAL DECISION SUPPORT
6.6.2 CLOSED-LOOP THERAPEUTIC AND DRUG DELIVERY SYSTEMS
6.6.3 DECENTRALIZED AND HYBRID CLINICAL TRIAL ENABLEMENT
6.6.4 CONTINUOUS DISEASE MANAGEMENT AND PREVENTIVE HEALTHCARE
6.6.5 ADVANCED BIOSENSING AND NON-INVASIVE DIAGNOSTICS
6.6.6 INTEGRATION WITH DIGITAL THERAPEUTICS AND PERSONALIZED MEDICINE
6.7 IMPACT OF AI/GEN AI
6.7.1 MARKET POTENTIAL OF AI/GEN AI
6.7.2 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
6.7.2.1 AI-driven continuous glucose monitoring and diabetes management at Dexcom
6.7.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
6.7.3.1 Wearable data analytics and AI-driven monitoring platforms
6.7.3.2 Digital health platforms, integration, and regulatory infrastructure
6.7.3.3 Clinical care, remote monitoring, and personalized therapeutics
6.7.4 USER READINESS AND IMPACT ASSESSMENT
6.7.4.1 User readiness
6.7.4.1.1 User A: Hospitals, clinics, and long-term care providers
6.7.4.1.2 User B: Pharma and biotech companies
6.7.4.2 Impact assessment
6.7.4.2.1 User A: Hospitals, clinics, and long-term care providers
6.7.4.2.1.1 Implementation
6.7.4.2.1.2 Impact
6.7.4.2.2 User B: Pharma and biotech companies
6.7.4.2.2.1 Implementation
6.7.4.2.2.2 Impact
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END-USE INDUSTRIES
8.4.1 UNMET NEEDS
8.4.2 END-USER EXPECTATIONS
8.5 MARKET PROFITABILITY
9 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 SMARTWATCHES
9.2.1 EXPANDING ROLE IN DIGITAL CLINICAL TRIALS AND REMOTE MONITORING
9.3 FITNESS BANDS
9.3.1 EMPHASIS ON REAL-WORLD EVIDENCE AND PATIENT-CENTRIC TRIAL DESIGNS
9.4 SMART RINGS
9.4.1 EMERGING CLINICAL-GRADE WEARABLES ENABLING EARLY DISEASE DETECTION AND CONTINUOUS MONITORING
9.5 CONTINUOUS GLUCOSE MONITORS
9.5.1 TRANSFORMING METABOLIC RESEARCH THROUGH REAL-TIME, HIGH-FREQUENCY DATA
9.6 PATCHES
9.6.1 CONTINUOUS, CLINICAL-GRADE MONITORING DRIVING ADOPTION IN DECENTRALIZED TRIALS
9.7 WEARABLE INJECTORS
9.7.1 GROWING DEMAND FOR SELF-ADMINISTRATION OF BIOLOGICS IN CHRONIC DISEASE MANAGEMENT
9.8 OTHER PRODUCTS
10 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA
10.1 INTRODUCTION
10.2 CARDIOVASCULAR
10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION
10.2.1.1 Focus on improving endpoint capture and long-term outcomes monitoring
10.2.2 HEART FAILURE
10.2.2.1 Continuous physiologic monitoring and AI-enabled decompensation prediction
10.2.3 HYPERTENSION
10.2.3.1 Cuffless monitoring and AI-driven adherence management enabling precision blood pressure control
10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION
10.2.4.1 Rapid expansion of AI-powered arrhythmia detection algorithms and regulatory-cleared wearable ECG technologies
10.2.5 PULMONARY HYPERTENSION
10.2.5.1 Growing use of wearable-enabled remote monitoring and AI analytics to generate objective, real-world functional endpoints
10.2.6 STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY
10.2.6.1 Wearable-enabled remote recovery monitoring and procedural optimization supporting precision structural heart care
10.3 ONCOLOGY
10.3.1 SOLID TUMORS
10.3.1.1 BREAST CANCER
10.3.1.1.1 Continuous wearable-based survivorship monitoring and decentralized oncology trials driving personalized long-term care models
10.3.1.2 LUNG CANCER
10.3.1.2.1 Constant respiratory monitoring and decentralized trial adoption
10.3.1.3 PROSTATE CANCER
10.3.1.3.1 Expansion of decentralized oncology trials and long-term survivorship management
10.3.1.4 COLORECTAL CANCER
10.3.1.4.1 Increasing adoption of decentralized oncology trials and remote post-surgical monitoring
10.3.1.5 BRAIN TUMOR
10.3.1.5.1 Remote neurologic surveillance and functional recovery tracking accelerating personalized care
10.3.1.6 OTHER SOLID TUMORS
10.3.2 HEMATOLOGIC MALIGNANCIES
10.3.2.1 LEUKEMIA
10.3.2.1.1 Wearable-enabled infection surveillance and treatment resilience monitoring transforming outpatient care
10.3.2.2 LYMPHOMA
10.3.2.2.1 Shift toward outpatient infusion centers, home-based recovery, and decentralized clinical trials
10.3.2.3 MULTIPLE MYELOMA
10.3.2.3.1 Real-time toxicity and mobility tracking using wearables in long-term management
10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES
10.3.3 DIABETES
10.3.3.1 Critical need for long-term, real-world metabolic monitoring
10.3.4 MENTAL HEALTH & BEHAVIORAL HEALTH
10.3.4.1 Rising global burden of psychiatric disorders
10.3.5 RESPIRATORY DISORDERS
10.3.5.1 Early exacerbation detection through continuous monitoring reduces hospitalization
10.3.6 LIFESTYLE & WELLNESS IMPROVEMENT
10.3.6.1 Continuous tracking for lifestyle optimization and preventive health risk management
10.3.7 NEUROLOGY
10.3.7.1 Wearable-based monitoring of neurological function and digital clinical endpoints in CNS disorders
10.3.8 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
10.3.8.1 Wearable-guided functional movement and chronic pain monitoring in musculoskeletal disorders
10.3.9 WOMEN'S HEALTH & REPRODUCTIVE HEALTH
10.3.9.1 Continuous physiological and reproductive cycle using wearables
10.3.10 OTHER DISEASES
11 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DRUG DISCOVERY
11.2.1 RECENT ADVANCES PROMOTE DISCOVERY OF DRUGS THROUGH WEARABLES IN PHARMA & BIOTECH
11.3 CLINICAL TRIALS
11.3.1 PHASE II
11.3.1.1 AI-enabled remote monitoring and adaptive trial designs accelerate adoption
11.3.2 PHASE III
11.3.2.1 Rapid expansion of decentralized and hybrid global trial models propels growth
11.3.3 PHASE IV
11.3.3.1 Ability to improve patient engagement and retention in long-duration studies drives market
11.4 MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
11.4.1 CONNECTED REMINDERS, PASSIVE MONITORING, AND PERSONALIZED NUDGES BOOST ADOPTION
11.5 CHRONIC DISEASE MONITORING
11.5.1 CONTINUOUS PHYSIOLOGICAL TRACKING AND PROACTIVE INTERVENTION CAPABILITIES INCREASE ADOPTION
11.6 PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
11.6.1 BIOMETRIC SENSING AND AI-DRIVEN COACHING RAISE DEMAND FOR WEARABLES
12 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOTECH COMPANIES
12.2.1 CLINICAL DIGITIZATION, REAL-WORLD EVIDENCE GENERATION, AND CONNECTED THERAPY MODELS DRIVE MARKET
12.3 HEALTHCARE PROVIDERS & CLINICIANS
12.3.1 REMOTE PATIENT MONITORING, PREVENTIVE CARE, AND DATA-DRIVEN CLINICAL DECISION SUPPORT BOOST GROWTH
12.4 CONTRACT RESEARCH ORGANIZATIONS
12.4.1 DECENTRALIZED TRIALS, WEARABLE DATA INTEGRATION, AND FASTER CLINICAL EXECUTION RAISE DEMAND
12.5 OTHER END USERS
13 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 High concentration of clinical research activity, clinical trial inefficiencies, and cost pressures to drive market
13.2.2 CANADA
13.2.2.1 Clinical research participation, public health burden, and digital health adoption to drive market
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Expanding clinical trial activity and regulatory leadership to drive market
13.3.2 FRANCE
13.3.2.1 Regulatory-first approach to healthcare and clinical innovation to drive market
13.3.3 UK
13.3.3.1 Real-world data integration and decentralized trial innovation to drive market
13.3.4 ITALY
13.3.4.1 Evolving clinical trial landscape and regulatory decentralization to drive market
13.3.5 SPAIN
13.3.5.1 Increasing investment in digital health infrastructure to drive market
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Clinical trial expansion and real-world data integration to drive market
13.4.2 JAPAN
13.4.2.1 Late-stage trial leadership and regulatory precision to drive market
13.4.3 INDIA
13.4.3.1 High-volume Phase III trial ecosystem and ABDM-driven digital health integration to drive market
13.4.4 AUSTRALIA
13.4.4.1 Early-phase trial leadership and remote care needs to drive market
13.4.5 SOUTH KOREA
13.4.5.1 Integrated clinical trial ecosystem and national health data infrastructure to drive market
13.4.6 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Clinical trial leadership and high diabetes burden to drive market
13.5.2 MEXICO
13.5.2.1 Regulatory reforms and Phase III trial expansion to drive market
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST & AFRICA
13.6.1 GCC
13.6.2 SAUDI ARABIA
13.6.2.1 Vision 2030–led digital health transformation to drive market
13.6.3 UAE
13.6.3.1 Digital health strategy, clinical trial expansion, and high healthcare investment to drive market
13.6.4 REST OF GCC
13.6.5 SOUTH AFRICA
13.6.5.1 Clinical trial leadership and decentralized care models to drive market
13.6.6 REST OF MIDDLE EAST & AFRICA
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026
14.3 REVENUE ANALYSIS, 2021–2025
14.4 MARKET SHARE ANALYSIS, 2025
14.5 BRAND/PRODUCT COMPARISON
14.6 COMPANY VALUATION AND FINANCIAL METRICS
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.7.1 STARS
14.7.2 EMERGING LEADERS
14.7.3 PERVASIVE PLAYERS
14.7.4 PARTICIPANTS
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
14.7.5.1 Company footprint
14.7.5.2 Region footprint
14.7.5.3 Product footprint
14.7.5.4 Therapeutic area footprint
14.7.5.5 Application footprint
14.7.5.6 End user footprint
14.8 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025
14.8.1 PROGRESSIVE COMPANIES
14.8.2 RESPONSIVE COMPANIES
14.8.3 DYNAMIC COMPANIES
14.8.4 STARTING BLOCKS
14.8.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025
14.8.5.1 List of start-ups/SMEs
14.8.5.2 Competitive benchmarking of start-ups/SMEs
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES AND APPROVALS
14.9.2 DEALS
14.9.3 OTHER DEVELOPMENTS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 DEXCOM, INC.
15.1.1.1 Business overview
15.1.1.2 Products offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches and approvals
15.1.1.3.2 Deals
15.1.1.4 MnM view
15.1.1.4.1 Right to win
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 ABBOTT
15.1.2.1 Business overview
15.1.2.2 Products offered
15.1.2.3 Recent developments
15.1.2.3.1 Product launches and approvals
15.1.2.3.2 Deals
15.1.2.3.3 Other developments
15.1.2.4 MnM view
15.1.2.4.1 Right to win
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses and competitive threats
15.1.3 MASIMO
15.1.3.1 Business overview
15.1.3.2 Products offered
15.1.3.3 Recent developments
15.1.3.3.1 Product launches and approvals
15.1.3.3.2 Deals
15.1.3.4 MnM view
15.1.3.4.1 Right to win
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses and competitive threats
15.1.4 BD
15.1.4.1 Business overview
15.1.4.2 Products offered
15.1.4.3 Recent developments
15.1.4.3.1 Product launches and approvals
15.1.4.3.2 Deals
15.1.4.4 MnM view
15.1.4.4.1 Right to win
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 APPLE INC.
15.1.5.1 Business overview
15.1.5.2 Products offered
15.1.5.3 Recent developments
15.1.5.3.1 Product launches and approvals
15.1.5.3.2 Deals
15.1.5.4 MnM view
15.1.5.4.1 Right to win
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses and competitive threats
15.1.6 BOSTON SCIENTIFIC CORPORATION
15.1.6.1 Business overview
15.1.6.2 Products offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.7 IRHYTHM TECHNOLOGIES, INC.
15.1.7.1 Business overview
15.1.7.2 Products offered
15.1.7.3 Recent developments
15.1.7.3.1 Product launches and approvals
15.1.7.3.2 Deals
15.1.8 KONINKLIJKE PHILIPS N.V.
15.1.8.1 Business overview
15.1.8.2 Products offered
15.1.8.3 Recent developments
15.1.8.3.1 Product launches and approvals
15.1.8.3.2 Deals
15.1.8.3.3 Other developments
15.1.9 MEDTRONIC
15.1.9.1 Business overview
15.1.9.2 Products offered
15.1.9.3 Recent developments
15.1.9.3.1 Deals
15.1.10 BIOINTELLISENSE, INC.
15.1.10.1 Business overview
15.1.10.2 Products offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches and approvals
15.1.10.3.2 Deals
15.1.11 F. HOFFMANN-LA ROCHE LTD
15.1.11.1 Business overview
15.1.11.2 Products offered
15.1.11.3 Recent developments
15.1.11.3.1 Product launches and approvals
15.1.12 GE HEALTHCARE
15.1.12.1 Business overview
15.1.12.2 Products offered
15.1.12.3 Recent developments
15.1.12.3.1 Product launches and approvals
15.1.12.3.2 Deals
15.1.13 BIOBEAT
15.1.13.1 Business overview
15.1.13.2 Products offered
15.1.13.3 Recent developments
15.1.13.3.1 Product launches and approvals
15.1.13.3.2 Deals
15.1.13.3.3 Other developments
15.1.14 EMPATICA INC.
15.1.14.1 Business overview
15.1.14.2 Products offered
15.1.14.3 Recent developments
15.1.14.3.1 Product launches and approvals
15.1.14.3.2 Deals
15.1.15 VITALCONNECT
15.1.15.1 Business overview
15.1.15.2 Products offered
15.1.15.3 Recent developments
15.1.15.3.1 Deals
15.1.15.3.2 Other developments
15.1.16 AMETRIS, LLC
15.1.16.1 Business overview
15.1.16.2 Products offered
15.1.16.3 Recent developments
15.1.16.3.1 Deals
15.1.17 ALIVECOR, INC.
15.1.17.1 Business overview
15.1.17.2 Products offered
15.1.17.3 Recent developments
15.1.17.3.1 Product launches and approvals
15.1.17.3.2 Deals
15.1.18 WITHINGS
15.1.18.1 Business overview
15.1.18.2 Products offered
15.1.18.3 Recent developments
15.1.18.3.1 Product launches and approvals
15.1.18.3.2 Deals
15.1.19 VIVALNK, INC.
15.1.19.1 Business overview
15.1.19.2 Products offered
15.1.19.3 Recent developments
15.1.19.3.1 Product launches and approvals
15.1.20 MEDIBIOSENSE
15.1.20.1 Business overview
15.1.20.2 Products offered
15.1.20.3 Recent developments
15.1.20.3.1 Product launches and approvals
15.2 OTHER PLAYERS
15.2.1 SIBEL HEALTH, INC.
15.2.2 BYTEFLIES
15.2.3 STRADOS LABS
15.2.4 ONERA TECHNOLOGIES B.V.
15.2.5 EPICORE BIOSYSTEMS, INC.
16 RESEARCH METHODOLOGY
16.1 RESEARCH APPROACH
16.1.1 SECONDARY RESEARCH
16.1.1.1 Key data from secondary sources
16.1.2 PRIMARY RESEARCH
16.1.2.1 Primary sources
16.1.2.2 Key data from primary sources
16.1.2.3 Breakdown of primary interviews
16.1.2.4 Insights from primary experts
16.2 RESEARCH METHODOLOGY DESIGN
16.3 MARKET SIZE ESTIMATION
16.4 DATA TRIANGULATION
16.5 RESEARCH ASSUMPTIONS
16.6 RESEARCH LIMITATIONS
16.6.1 METHODOLOGY-RELATED
16.6.2 SCOPE-RELATED
16.7 RISK ASSESSMENT
17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 EXCHANGE RATES FOR CURRENCY CONVERSION
TABLE 2 IMPACT OF PORTER’S FIVE FORCES
TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM
TABLE 4 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2025
TABLE 5 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2025
TABLE 6 IMPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 7 EXPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 8 KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 9 CASE 1: CLINICAL GRADE WEARABLE VITAL SIGNS MONITORING IN NEONATAL & MATERNAL TRIALS
TABLE 10 CASE 2: MULTI LEAD WEARABLE ECG MONITORING FOR CARDIOLOGY TRIALS
TABLE 11 CASE 3: CONTINUOUS RESPIRATORY MONITORING IN CHRONIC LUNG DISEASE
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES
TABLE 14 LIST OF PATENTS/PATENT APPLICATIONS
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 21 KEY BUYING CRITERIA, BY END USER
TABLE 22 UNMET NEEDS IN WEARABLES IN PHARMA & BIOTECH MARKET
TABLE 23 END-USER EXPECTATIONS IN WEARABLES IN PHARMA & BIOTECH MARKET
TABLE 24 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 25 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (THOUSAND UNITS)
TABLE 26 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES
TABLE 27 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES, BY REGION, 2024–2031 (USD MILLION)
TABLE 28 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS
TABLE 29 WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS
TABLE 31 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS
TABLE 33 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES
TABLE 35 WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS
TABLE 37 WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS
TABLE 39 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 41 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 42 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION
TABLE 44 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE
TABLE 46 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE, BY REGION, 2024–2031 (USD MILLION)
TABLE 47 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION
TABLE 48 WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/STROKE PREVENTION
TABLE 50 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/
STROKE PREVENTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION
TABLE 52 WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY
TABLE 54 WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 56 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS
TABLE 58 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 59 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 WEARABLES IN PHARMA & BIOTECH MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 WEARABLES IN PHARMA & BIOTECH MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 WEARABLES IN PHARMA & BIOTECH MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 WEARABLES IN PHARMA & BIOTECH MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 WEARABLES IN PHARMA & BIOTECH MARKET FOR BRAIN TUMOR, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES
TABLE 67 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 68 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 WEARABLES IN PHARMA & BIOTECH MARKET FOR LEUKEMIA, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 WEARABLES IN PHARMA & BIOTECH MARKET FOR LYMPHOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 WEARABLES IN PHARMA & BIOTECH MARKET FOR MULTIPLE MYELOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER HEMATOLOGIC MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES
TABLE 74 WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH
TABLE 76 WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS
TABLE 78 WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT
TABLE 80 WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY
TABLE 82 WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
TABLE 84 WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH
TABLE 86 WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES
TABLE 88 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 90 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY
TABLE 91 WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS
TABLE 93 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 94 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS
TABLE 96 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS
TABLE 98 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS
TABLE 100 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
TABLE 102 WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING
TABLE 104 WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
TABLE 106 WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 108 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES
TABLE 109 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS
TABLE 111 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS
TABLE 113 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS
TABLE 115 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 116 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 120 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 124 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 127 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 128 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 129 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 134 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 136 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 137 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 138 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 139 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 143 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 144 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 147 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 148 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 149 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 153 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 156 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 157 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 158 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 159 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 162 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 163 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 164 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 165 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 166 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 169 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 170 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 171 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 173 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 174 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 175 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 176 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 180 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 181 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 182 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 183 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 184 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 186 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 187 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 189 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 190 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 191 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 192 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 193 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 194 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 198 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 200 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 201 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 202 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 205 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 207 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 1 EXCHANGE RATES FOR CURRENCY CONVERSION
TABLE 2 IMPACT OF PORTER’S FIVE FORCES
TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM
TABLE 4 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2025
TABLE 5 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2025
TABLE 6 IMPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 7 EXPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 8 KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 9 CASE 1: CLINICAL GRADE WEARABLE VITAL SIGNS MONITORING IN NEONATAL & MATERNAL TRIALS
TABLE 10 CASE 2: MULTI LEAD WEARABLE ECG MONITORING FOR CARDIOLOGY TRIALS
TABLE 11 CASE 3: CONTINUOUS RESPIRATORY MONITORING IN CHRONIC LUNG DISEASE
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES
TABLE 14 LIST OF PATENTS/PATENT APPLICATIONS
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 21 KEY BUYING CRITERIA, BY END USER
TABLE 22 UNMET NEEDS IN WEARABLES IN PHARMA & BIOTECH MARKET
TABLE 23 END-USER EXPECTATIONS IN WEARABLES IN PHARMA & BIOTECH MARKET
TABLE 24 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 25 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (THOUSAND UNITS)
TABLE 26 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES
TABLE 27 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES, BY REGION, 2024–2031 (USD MILLION)
TABLE 28 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS
TABLE 29 WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS
TABLE 31 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS
TABLE 33 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES
TABLE 35 WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS
TABLE 37 WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS
TABLE 39 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 41 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 42 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION
TABLE 44 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE
TABLE 46 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE, BY REGION, 2024–2031 (USD MILLION)
TABLE 47 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION
TABLE 48 WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/STROKE PREVENTION
TABLE 50 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/
STROKE PREVENTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION
TABLE 52 WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY
TABLE 54 WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 56 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS
TABLE 58 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 59 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 WEARABLES IN PHARMA & BIOTECH MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 WEARABLES IN PHARMA & BIOTECH MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 WEARABLES IN PHARMA & BIOTECH MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 WEARABLES IN PHARMA & BIOTECH MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 WEARABLES IN PHARMA & BIOTECH MARKET FOR BRAIN TUMOR, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES
TABLE 67 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 68 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 WEARABLES IN PHARMA & BIOTECH MARKET FOR LEUKEMIA, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 WEARABLES IN PHARMA & BIOTECH MARKET FOR LYMPHOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 WEARABLES IN PHARMA & BIOTECH MARKET FOR MULTIPLE MYELOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER HEMATOLOGIC MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES
TABLE 74 WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH
TABLE 76 WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS
TABLE 78 WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT
TABLE 80 WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY
TABLE 82 WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
TABLE 84 WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH
TABLE 86 WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES
TABLE 88 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 90 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY
TABLE 91 WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS
TABLE 93 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 94 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS
TABLE 96 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS
TABLE 98 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS
TABLE 100 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
TABLE 102 WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING
TABLE 104 WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
TABLE 106 WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 108 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES
TABLE 109 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS
TABLE 111 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS
TABLE 113 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS
TABLE 115 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 116 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 120 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 124 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 127 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 128 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 129 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 134 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 136 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 137 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 138 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 139 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 143 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 144 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 147 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 148 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 149 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 153 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 156 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 157 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 158 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 159 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 162 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 163 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 164 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 165 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 166 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 169 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 170 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 171 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 173 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 174 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 175 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 176 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 180 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 181 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 182 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 183 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 184 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 186 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 187 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 189 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 190 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 191 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 192 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 193 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 194 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 198 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 200 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 201 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 202 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 205 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 207 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL WEARABLES IN PHARMA & BIOTECH MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN PHARMA & BIOTECH MARKET
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF WEARABLES IN PHARMA & BIOTECH MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN WEARABLES IN PHARMA & BIOTECH MARKET
FIGURE 6 ASIA PACIFIC TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD
FIGURE 7 EXPANSION OF DECENTRALIZED AND REMOTE PATIENT-CENTRIC TRIALS TO DRIVE MARKET
FIGURE 8 PHARMACEUTICAL & BIOTECH COMPANIES AND US ACCOUNTED FOR LARGEST SHARES IN 2025
FIGURE 9 INDIA TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD
FIGURE 10 PORTER’S FIVE FORCES ANALYSIS
FIGURE 11 SUPPLY CHAIN ANALYSIS
FIGURE 12 ECOSYSTEM ANALYSIS
FIGURE 13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 15 PATENT PUBLICATION TRENDS, 2015–2026
FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 17 PATENT ANALYSIS
FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 19 KEY BUYING CRITERIA, BY END USER
FIGURE 20 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT
FIGURE 21 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT
FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025
FIGURE 23 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 24 BRAND/PRODUCT COMPARISON
FIGURE 25 FINANCIAL METRICS (EV/EBITDA)
FIGURE 26 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 27 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 28 COMPANY FOOTPRINT
FIGURE 29 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025
FIGURE 30 DEXCOM, INC.: COMPANY SNAPSHOT
FIGURE 31 ABBOTT: COMPANY SNAPSHOT
FIGURE 32 MASIMO: COMPANY SNAPSHOT
FIGURE 33 BD: COMPANY SNAPSHOT
FIGURE 34 APPLE INC.: COMPANY SNAPSHOT
FIGURE 35 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
FIGURE 36 IRHYTHM TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 37 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
FIGURE 38 MEDTRONIC: COMPANY SNAPSHOT
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 41 RESEARCH DESIGN
FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 43 BOTTOM-UP APPROACH
FIGURE 44 TOP-DOWN APPROACH
FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 47 DATA TRIANGULATION
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL WEARABLES IN PHARMA & BIOTECH MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN PHARMA & BIOTECH MARKET
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF WEARABLES IN PHARMA & BIOTECH MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN WEARABLES IN PHARMA & BIOTECH MARKET
FIGURE 6 ASIA PACIFIC TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD
FIGURE 7 EXPANSION OF DECENTRALIZED AND REMOTE PATIENT-CENTRIC TRIALS TO DRIVE MARKET
FIGURE 8 PHARMACEUTICAL & BIOTECH COMPANIES AND US ACCOUNTED FOR LARGEST SHARES IN 2025
FIGURE 9 INDIA TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD
FIGURE 10 PORTER’S FIVE FORCES ANALYSIS
FIGURE 11 SUPPLY CHAIN ANALYSIS
FIGURE 12 ECOSYSTEM ANALYSIS
FIGURE 13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 15 PATENT PUBLICATION TRENDS, 2015–2026
FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 17 PATENT ANALYSIS
FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 19 KEY BUYING CRITERIA, BY END USER
FIGURE 20 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT
FIGURE 21 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT
FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025
FIGURE 23 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 24 BRAND/PRODUCT COMPARISON
FIGURE 25 FINANCIAL METRICS (EV/EBITDA)
FIGURE 26 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 27 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 28 COMPANY FOOTPRINT
FIGURE 29 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025
FIGURE 30 DEXCOM, INC.: COMPANY SNAPSHOT
FIGURE 31 ABBOTT: COMPANY SNAPSHOT
FIGURE 32 MASIMO: COMPANY SNAPSHOT
FIGURE 33 BD: COMPANY SNAPSHOT
FIGURE 34 APPLE INC.: COMPANY SNAPSHOT
FIGURE 35 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
FIGURE 36 IRHYTHM TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 37 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
FIGURE 38 MEDTRONIC: COMPANY SNAPSHOT
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 41 RESEARCH DESIGN
FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 43 BOTTOM-UP APPROACH
FIGURE 44 TOP-DOWN APPROACH
FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 47 DATA TRIANGULATION
